Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 6/20 | 0.41 |
| ▸ | CBFB | Q13951 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11843651 | 0.80 | MAPT (0.36) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL28920099 | 0.77 | ALDH1A1 (0.33) | NPC1RAB9AL3MBTL1KDM4EMAPT | |
| SCHEMBL990710 | 0.77 | MAPT (0.48) | NPC1RAB9AL3MBTL1KDM4EMAPT | |
| SCHEMBL8311607 | 0.74 | KDM4E (0.56) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL5578303 | 0.73 | — | — | |
| SCHEMBL6924808 | 0.71 | SMN1; SMN2 (0.47) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL3327100 | 0.71 | KDM4E (0.49) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL14157267 | 0.71 | NPC1 (0.47) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL19691765 | 0.71 | BTK (0.47) | METAP1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL10982107 | 0.71 | NPC1 (0.44) | METAP1NPC1RAB9AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011089132-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20090318443-A1 | KINASE INHIBITORS | BONJOUKLIAN ROSANNE | 2009-12-24 | — | — | US | disclosed |
| US-7582652-B2 | Suppression cytokines, tumor necrosis factor; melanoma | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1713805-B1 | KINASE INHIBITORS | LILLY CO ELI (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090036445-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1713805-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075478-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036445-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | METAP1 2567/4885NPC1 2479/4885RAB9A 2018/4885 |
| US-20090318443-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | METAP1 2567/4885NPC1 2479/4885RAB9A 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.